Investing.com -- GRI Bio Inc (NASDAQ:GRI) stock soared 37.6% in premarket trading Wednesday after the company reported additional positive data from its Phase 2a clinical study of GRI-0621 in ...
LA JOLLA, CA - GRI Bio, Inc. (NASDAQ:GRI) announced additional positive data from its Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), showing the drug candidate’s potential ...
Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons that can correct multiple disease-causing mutations at once. Unlike ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...
Recent GLP-1 (glucagon-like peptide-1) obesity treatments such as ‘Wegovy’ and ‘Mounjaro’ have gained immense popularity, but the so-called "yo-yo effect," where weight rebounds after discontinuing ...
Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. The biotech is pioneering treatments based on base ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results